The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.
Hosted on MSN38m
No Clear Winner in SGLT2 Showdown for Cardiovascular DiseaseTaken at face value, the results would suggest that the three SGLT2 inhibitors are "virtually identical," according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback